Qiagen reported strong Q1 22 results, with both sales and profitability ahead of expectations. Growth/recovery was witnessed for both the non-COVID-19 and COVID-19 offerings. Moreover, management upgraded its 2022 guidance. These results are also an encouraging read-across for other testing firms in our coverage. Overall, our positive stock recommendation is reiterated, also on the back of Qiagen’s sustained innovations resulting in broad-based offerings.
29 Apr 2022
Stronger-than-expected Q1, followed by guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Stronger-than-expected Q1, followed by guidance upgrade
- Published:
29 Apr 2022 -
Author:
Anas PATEL -
Pages:
4
Qiagen reported strong Q1 22 results, with both sales and profitability ahead of expectations. Growth/recovery was witnessed for both the non-COVID-19 and COVID-19 offerings. Moreover, management upgraded its 2022 guidance. These results are also an encouraging read-across for other testing firms in our coverage. Overall, our positive stock recommendation is reiterated, also on the back of Qiagen’s sustained innovations resulting in broad-based offerings.